Optimization of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy for Japanese patients with urothelial carcinomaTaketo Kawai, Haruki Kume, Masahiro Yamamoto et al.|Japanese Journal of Clinical Oncology|2025Cited by 7
Prognostic impact of histological discordance between transurethral resection and radical cystectomyAyumu Matsuda, Rikiya Taoka, Jun Miki et al.|British Journal of Urology|2024Cited by 4
Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomyYuta Yamada, Haruki Kume, Yoichi Fujii et al.|Scientific Reports|2024Cited by 4
The first real-world evidence on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin followed by switch maintenance avelumab in advanced urothelial carcinoma: a propensity score-matched studySatoru Taguchi, Haruki Kume, Taketo Kawai et al.|International Journal of Clinical Oncology|2025Cited by 3